Bioasis Technologies Inc. announced that it has entered into a research collaboration with Janssen Biotech, Inc. Under the terms of the agreement, Janssen will have the option to research, develop and commercialize novel products based on Bioasis' xB3TM platform. The agreement was facilitated by Johnson & Johnson Innovation.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 CAD | -.--% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 289K | |
+26.28% | 42.68B | |
-3.99% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.36% | 24.94B | |
-21.47% | 18.96B | |
+27.58% | 12.3B | |
-2.75% | 11.95B | |
-2.02% | 11.55B |
- Stock Market
- Equities
- BTI Stock
- News Bioasis Technologies Inc.
- Bioasis Technologies Inc. Enters Research Collaboration with Janssen Biotech, Inc